查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1808376

按產品類型、技術、應用和最終用戶照護現場診斷分子診斷市場 - 全球預測 2025-2030

Point of Care Molecular Diagnostics Market by Product Type, Technology, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計照護現場診斷市場規模到 2024 年將達到 52.6 億美元，到 2025 年將達到 56.4 億美元，到 2030 年將達到 80.9 億美元，複合年成長率為 7.42%。

主要市場統計數據
基準年2024年 52.6億美元
預計2025年 56.4億美元
預測年份 2030 80.9億美元
複合年成長率（%） 7.42%

利用快速的即時分子診斷技術，增強即時臨床決策能力，為以患者為中心的醫療照護的未來鋪平道路

即時診斷 (POC) 分子診斷技術正在透過快速、準確、分散式檢查，徹底改變患者照護的模式。微型核酸擴增系統的引入，加上數位化連接，正在加速從集中式實驗室轉向床邊檢測環境的轉變。這種轉變使臨床醫生能夠在需要時做出明智的決策，從而縮短週轉時間並最佳化治療方案。

隨著技術創新和醫療保健服務模式的變化，POC分子診斷正在快速發展

近年來，科技取得了顯著進步，重塑了即時診斷 (POC) 分子診斷生態系統。微流體晶片設計和試劑配方的創新顯著縮短了檢測週轉時間，使關鍵決策能夠在幾分鐘內而非幾小時內做出。同時，可攜式硬體與雲端基礎資料平台的整合，實現了分散式檢查站點與中心實驗室網路之間的無縫連接。因此，臨床醫生可以即時獲得可操作的檢測結果、患者病史和群體健康指標。

評估 2025 年美國關稅對即時分子診斷供應鏈和成本結構的累積影響

2025年美國加徵關稅為即時診斷（POC）分子診斷試劑的供應商和最終用戶帶來了新的挑戰。檢測儀器以及耗材試劑和套件都面臨進口關稅上調，這將直接影響成本結構。為此，製造商正在加快在地化生產和簽訂替代採購協議的步伐，以降低利潤率下降的風險。

根據產品類型、技術應用和最終用戶，揭示照護現場分子診斷市場的關鍵細分洞察

全面審視產品類型後發現，在設計和便攜性持續創新的推動下，儀器銷售仍是平台普及的關鍵。同時，隨著檢測項目擴展至多重檢測組合和新型生物標記物，試劑和套件的需求仍然強勁。同時，由於實驗室和醫療網路更注重數據分析和無縫互通性而非獨立硬體，軟體產品也越來越受歡迎。

了解影響 POC 在美洲、中東/非洲和亞太地區傳播的區域動態

在美洲，持續的醫療基礎設施投資和有利的法規環境正在加速POC在都市區地區的普及。聯邦政府為加強疫情防控舉措，已為快速檢測的開發提供了資金，而私人醫療網路則持續擴展門診和社區健康中心的照護現場能力。

揭示透過夥伴關係、合併和產品開發推動即時分子診斷創新的關鍵參與者的策略性舉措

產業領導者正優先考慮策略聯盟和收購，以擴大照護現場分子診斷產品組合。主要的診斷開發商正在與專業試劑製造商合作，共同開發專有的檢測化學方法，並簡化夥伴關係鏈。同時，許多公司宣布對軟體分析公司進行補充收購，以增強其在分散式檢測網路中的資料整合能力。

為行業領導者制定可行的建議，以利用即時分子診斷的機會並增強其競爭優勢

為了滿足日益成長的快速分子檢測需求，產業領導者應投資於支援模組化檢測擴展的靈活平台架構。設計能夠相容於各種試劑盒的系統，使公司能夠快速應對新出現的病原體威脅和不斷變化的臨床重點。同樣重要的是與試劑製造商建立策略合作夥伴關係，以確保可靠的高品質化學品供應。

了解我們嚴謹的調查方法，這些方法支撐我們全面、可靠的 POC 分子診斷洞察分析

此項分析基於嚴謹的研究框架，結合了對多個地區的高階主管、實驗室主任和臨床終端使用者的深入訪談。這些訪談提供了關於採用促進因素、技術偏好以及 POC 應用特有的營運挑戰的第一手見解。

關於照護現場診斷在現代醫療保健中的變革潛力和策略重要性的總結性觀點

照護現場。隨著平台變得更加緊湊、方便用戶使用和數位互聯，它們有可能重新定義診斷工作流程，並改善各種醫療環境中的患者治療效果。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 將基於 CRISPR 的檢測方法整合到可攜式照護現場平台中，以快速識別病原體
  • 推出支援智慧型手機的分子診斷設備，用於分散式患者檢測
  • 在照護現場分子診斷結果解釋中實施人工智慧驅動的預測分析
  • 擴大多重PCR檢測規模，以便在照護端同時檢測多種感染疾病
  • 開發等溫擴增技術，實現低成本、現場可部署的分子偵測解決方案
  • 監管部門的核准加速了下一代基於墨盒的分子診斷系統的商業化
  • 診斷公司與遠端醫療提供者合作簡化遠距分子檢測工作流程
  • 用於家庭感染疾病監測和管理的家用分子檢測套組的成長
  • 新興的紙基微流體平台，用於資源有限環境下的超低成本即時分子診斷
  • 門診和分散護理機構對快速腫瘤生物標記檢測的需求不斷增加

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8照護現場診斷分子診斷市場（依產品類型）

  • 裝置
  • 試劑和套件
  • 軟體

第9章照護現場分子診斷市場（按技術）

  • 基於基因序列
  • 雜交基地
  • 恒溫核酸增幅技術（INAAT）
  • 基於微陣列
  • 基於PCR

第 10 章。照護現場分子診斷市場（按應用）

  • 心臟病學
  • 基因檢測
    • 攜帶者篩檢
    • 新生兒篩檢
    • 產前檢查
  • 感染疾病
    • 胃腸道感染疾病
    • 呼吸道感染疾病
    • 性行為感染傳染病
    • 熱帶疾病
  • 腫瘤學
    • 液態生物檢體
    • 突變分析
    • 腫瘤基因面板

第 11 章。照護現場分子診斷市場（按最終用戶）

  • 診所
  • 診斷實驗室
  • 居家照護環境
  • 醫院

12. 美國照護現場診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

13. 歐洲、中東和非洲照護現場診斷市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

14. 亞太地區照護現場分子診斷市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • ACON LABS INC.
    • Binx Health, inc.
    • bioMerieux SA
    • Cardinal Health, Inc.
    • Chembio Diagnostics Inc.
    • Co-Diagnostics, Inc.
    • Danaher Corporation
    • DiaSorin SpA
    • EKF Diagnostics Holdings
    • FHoffmann-La Roche AG
    • Genomadix Inc. by LuminUltra Technologies Ltd.
    • Henry Schein, Inc.
    • Meridian Bioscience, Inc.
    • Novartis AG
    • OraSure Technologies, Inc.
    • Pfizer, Inc.
    • QIAGEN NV
    • Quidel Corporation
    • SD Biosensor
    • Sekisui Diagnostics
    • SHUWEN BIOTECH CO., LTD
    • Siemens Healthineers AG
    • Sysmex Corporation
    • Thermo Fisher Scientific Inc.

第16章 研究人工智慧

第17章 研究統計

第18章 研究聯絡人

第19章 研究報導

第20章 附錄

Product Code: MRR-5A2C6AA669BE

The Point of Care Molecular Diagnostics Market was valued at USD 5.26 billion in 2024 and is projected to grow to USD 5.64 billion in 2025, with a CAGR of 7.42%, reaching USD 8.09 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.26 billion
Estimated Year [2025] USD 5.64 billion
Forecast Year [2030] USD 8.09 billion
CAGR (%) 7.42%

Unlocking the Future of Patient-Centered Care Through Rapid Point of Care Molecular Diagnostics That Enhance Clinical Decision Making Across Healthcare Settings

Point of care molecular diagnostics is transforming the delivery of patient care by enabling rapid, accurate, and decentralized testing. The introduction of miniaturized nucleic acid amplification systems combined with digital connectivity has accelerated the shift from centralized laboratories to bedside testing environments. This transition empowers clinicians to make informed decisions at the point of need, reducing turnaround times and optimizing treatment pathways.

Emerging assay formats leverage isothermal amplification, microfluidics, and integrated cartridge-based workflows to simplify sample preparation and analysis. As a result, healthcare professionals can detect infectious pathogens, genetic mutations, and oncological biomarkers in a fraction of the time required by traditional laboratory platforms. This evolution aligns with the broader trend toward personalized medicine, where diagnostic insights drive targeted therapies and improve clinical outcomes.

Furthermore, evolving reimbursement frameworks and regulatory guidelines have catalyzed the adoption of these devices in diverse care settings. Strategic collaborations between diagnostic developers, healthcare institutions, and digital health companies are fostering interoperability and data integration, creating an ecosystem that supports real-time surveillance and longitudinal patient monitoring.

The lessons learned from global pandemic responses have underscored the critical importance of rapid molecular detection in controlling outbreaks and mitigating public health risks. By deploying portable diagnostic units in field settings and resource-limited environments, stakeholders can identify and contain emerging threats before they spread. Consequently, this capability not only enhances the resilience of healthcare systems but also supports broader public health initiatives aimed at disease surveillance and prevention.

Charting the Rapid Evolution of Point of Care Molecular Diagnostics Driven by Technological Innovation and Shifting Healthcare Delivery Models

Recent years have witnessed remarkable technological advances that are reshaping the point of care molecular diagnostics ecosystem. Innovations in microfluidic chip design and reagent formulation have dramatically reduced assay turnaround times, allowing critical decisions to be made within minutes rather than hours. Simultaneously, the integration of portable hardware with cloud-based data platforms is enabling seamless connectivity between decentralized test sites and central laboratory networks. As a result, clinicians benefit from immediate access to actionable test results alongside patient histories and population health metrics.

Concurrently, the rise of machine learning and artificial intelligence has begun to inform assay interpretation and workflow optimization. Predictive algorithms can now help flag inconsistent assay outputs, standardize quality control, and even suggest differential diagnoses based on molecular signatures. These capabilities not only improve analytical accuracy but also reduce the burden on healthcare professionals, who face increasing pressures related to staffing shortages and rising case volumes.

Regulatory bodies and payers are responding to these shifts by streamlining approval pathways and updating reimbursement codes to reflect the value proposition of rapid molecular assays. In parallel, healthcare systems are exploring value-based care models that incentivize the reduction of hospital stays and readmissions through timely diagnostics. Taken together, these transformative forces are charting a new era in which point of care molecular testing becomes an indispensable component of efficient, patient-centered healthcare delivery.

Assessing the Cumulative Impact of 2025 United States Tariff Measures on Point of Care Molecular Diagnostics Supply Chains and Cost Structures

The imposition of enhanced tariff measures by the United States in 2025 has introduced a new set of challenges for suppliers and end users of point of care molecular diagnostics. Instruments, along with their consumable reagents and kits, are facing increased import duties that directly impact cost structures. In response, manufacturers are accelerating efforts to localize production and secure alternative sourcing agreements, thereby mitigating the risk of margin erosion.

As reagents become subject to higher duties, distributors and diagnostic laboratories are reevaluating inventory strategies and pricing models. Some organizations have begun renegotiating long-term contracts to achieve volume-based discounts or to shift toward vendor-managed inventory solutions that reduce holding costs. Despite these adjustments, smaller clinics and home care providers may experience delayed adoption of new assays due to constrained budgets and tighter procurement cycles.

Yet, amid these headwinds, a silver lining has emerged: renewed interest in domestic supply chain resilience. Stakeholders are exploring partnerships with contract manufacturing organizations and establishing regional distribution hubs to shorten lead times and reduce exposure to global logistics disruptions. Ultimately, the 2025 tariff environment is prompting a strategic realignment across the value chain as industry participants strive to balance cost pressures against the imperative for rapid, reliable molecular diagnostics.

Illuminating Key Segmentation Insights Across Product Types Technologies Applications and End Users in the Point of Care Molecular Diagnostics Market

A comprehensive examination of product categories reveals that instrument sales continue to serve as a cornerstone for platform adoption, driven by ongoing innovations in design and portability. At the same time, reagents and kits are experiencing robust demand as assay menus expand to include multiplex panels and novel biomarkers. Software offerings, meanwhile, are gaining traction as laboratories and care networks prioritize data analytics and seamless interoperability over standalone hardware.

When analyzing technological underpinnings, genetic sequencing-based approaches have begun to penetrate the point of care arena by offering comprehensive genomic insights in near real time. Hybridization-based methods maintain their stronghold in targeted applications, while isothermal nucleic acid amplification technology provides cost-effective, rapid detection in resource-constrained environments. Furthermore, microarray-based solutions are carving out niches in specialized diagnostics, and PCR-based platforms remain the predominant choice for high-sensitivity assays.

In terms of clinical applications, cardiology assays are emerging as a critical tool for identifying acute cardiac events and guiding treatment pathways. Genetic testing has diversified beyond traditional carrier screening to encompass newborn and prenatal diagnostics, delivering actionable information earlier in the patient journey. Infectious disease testing continues to evolve with expanded panels for gastrointestinal, respiratory, sexually transmitted, and tropical pathogens. Oncology has witnessed significant growth in liquid biopsy techniques, mutation profiling, and onco-gene panels that support personalized cancer management.

Finally, end user dynamics underscore a shift toward decentralized models. Clinics are investing in compact systems to deliver same-visit results, whereas diagnostic laboratories reinforce centralized capabilities with point of care extensions. Home care settings are piloting user-friendly devices that enable remote monitoring, and hospitals are integrating molecular diagnostics into emergency and surgical workflows to enhance patient throughput.

Revealing Regional Dynamics Shaping Adoption of Point of Care Molecular Diagnostics Across the Americas Europe Middle East and Africa and Asia-Pacific

In the Americas, sustained investment in healthcare infrastructure and a supportive regulatory environment have accelerated the deployment of point of care molecular diagnostics across both urban and rural settings. Federal initiatives aimed at strengthening pandemic preparedness have unlocked funding for rapid test development, while private healthcare networks continue to expand point of care capabilities within ambulatory care and community health centers.

Across Europe Middle East and Africa, diverse regulatory landscapes present both challenges and opportunities. In Western Europe, harmonized approval processes and robust reimbursement schemes have fostered early adoption of advanced molecular platforms. Meanwhile, in emerging markets, flexible pricing models and public-private partnerships are instrumental in scaling assay deployment. Regions facing infrastructure limitations are increasingly leveraging portable, battery-powered devices to bridge diagnostic gaps.

Asia-Pacific is witnessing some of the fastest growth rates globally, fueled by large patient populations and proactive government initiatives focused on disease surveillance. Economic growth in key markets has led to enhanced healthcare spending, while innovative payment models-such as subscription-based reagent plans-are unlocking access in mid-tier hospitals and clinics. Additionally, collaborations with local manufacturers are reducing costs and expediting market entry for new assays.

Uncovering Strategic Moves of Leading Players Driving Innovation in Point of Care Molecular Diagnostics Through Partnerships Mergers and Product Development

Leading industry participants are prioritizing strategic collaborations and acquisitions to broaden their point of care molecular diagnostics portfolios. Major diagnostic developers are forging partnerships with specialty reagent producers to co-develop proprietary assay chemistries and streamline supply chains. Simultaneously, a number of players have announced bolt-on acquisitions of software analytics firms to elevate data integration capabilities across decentralized testing networks.

On the innovation front, several organizations are piloting next-generation sequencing modules that can be tethered to mobile workstations, thereby bringing comprehensive genomic profiling to outpatient settings. Other companies are doubling down on isothermal amplification technology, aiming to deliver low-cost, high-throughput solutions amenable to field deployment in emerging markets. Across the board, differentiated assay sensitivity and specificity have become key competitive levers.

Moreover, an increasing emphasis on digital health has prompted diagnostic vendors to bundle connectivity services, offering cloud-based result management and remote quality-control dashboards. This shift is reshaping go-to-market strategies as customers demand turnkey solutions that encompass hardware, consumables, and software under unified service agreements.

Formulating Actionable Recommendations for Industry Leaders to Capitalize on Opportunities in Point of Care Molecular Diagnostics and Enhance Competitive Advantage

To capitalize on the growing demand for rapid molecular testing, industry leaders should invest in flexible platform architectures that support modular assay expansion. By designing systems capable of accommodating a wide range of reagent cartridges, organizations can swiftly respond to emerging pathogen threats and shifting clinical priorities. Equally important is the cultivation of strategic alliances with reagent manufacturers to ensure a reliable supply of high-quality chemistries.

Furthermore, aligning product development roadmaps with evolving regulatory frameworks and reimbursement pathways will expedite market access. Cross-functional task forces that include regulatory experts, clinical liaisons, and health economics professionals can proactively address compliance requirements and articulate value propositions to payers. In parallel, establishing training programs and remote support capabilities will enhance user adoption and minimize operator errors in decentralized environments.

Finally, enhancing supply chain resilience through the localization of key manufacturing processes and the creation of regional distribution hubs will mitigate the impact of future trade disruptions. Coupling these efforts with data-driven demand forecasting tools will optimize inventory levels and reduce lead times. By adopting these measures, decision-makers can secure a competitive edge while delivering reliable point of care diagnostics to a broad spectrum of end users.

Detailing the Rigorous Research Methodology Underpinning the Analysis for Comprehensive and Reliable Point of Care Molecular Diagnostics Insights

This analysis is grounded in a rigorous research framework that combines in-depth primary interviews with senior executives, laboratory directors, and clinical end users across multiple geographies. These conversations provided first-hand insights into adoption drivers, technology preferences, and operational challenges specific to point of care molecular applications.

Secondary research complemented these qualitative findings by drawing on peer-reviewed publications, regulatory filings, and corporate release documents. Data from industry whitepapers and public health agency reports were triangulated against proprietary databases to validate trends and ensure consistency. Each data point underwent cross-verification through multiple sources to maintain accuracy and objectivity.

Our segmentation approach aligns product types, technology modalities, clinical applications, and end user categories to deliver a nuanced understanding of market dynamics. Regional analyses were informed by economic indicators, healthcare spending patterns, and local regulatory landscapes. Key performance metrics and thematic insights were further tested through scenario planning exercises to assess resilience under varying market conditions.

Quality control measures-including independent peer reviews, editorial audits, and methodological sanity checks-ensure that findings meet the highest standards of reliability. The resulting perspectives offer stakeholders a robust foundation for strategic decision-making and informed investment in point of care molecular diagnostics.

Concluding Perspectives on the Transformative Potential and Strategic Imperatives of Point of Care Molecular Diagnostics in Modern Healthcare

Point of care molecular diagnostics stands at the intersection of technological innovation, clinical necessity, and economic pragmatism. As platforms become more compact, user friendly, and digitally connected, they have the potential to redefine diagnostic workflows and enhance patient outcomes across diverse care settings.

Industry participants must remain vigilant in adapting to shifting regulatory requirements, supply chain challenges, and evolving reimbursement landscapes. By embracing strategic partnerships, investing in modular architectures, and aligning closely with clinical stakeholders, organizations can harness the transformative power of rapid molecular testing. Ultimately, those who proactively integrate these solutions into healthcare delivery models will lead the migration toward faster, more personalized care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Integration of CRISPR-based detection methods into portable point-of-care platforms for rapid pathogen identification
  • 5.2. Adoption of smartphone-enabled molecular diagnostic devices for decentralized patient testing
  • 5.3. Implementation of AI-driven predictive analytics in point-of-care molecular diagnostic result interpretation
  • 5.4. Expansion of multiplex PCR assays for simultaneous detection of multiple infectious diseases at point of care
  • 5.5. Development of isothermal amplification technologies for low-cost, field-deployable molecular testing solutions
  • 5.6. Regulatory approvals accelerating commercialization of next-generation cartridge-based molecular diagnostic systems
  • 5.7. Partnerships between diagnostics firms and telehealth providers to streamline remote molecular testing workflows
  • 5.8. Growth of home-based molecular testing kits for at-home infectious disease monitoring and management
  • 5.9. Emergence of paper-based microfluidic platforms for ultra-low-cost point-of-care molecular diagnostics in resource-limited settings
  • 5.10. Increasing demand for rapid oncology biomarker assays in outpatient clinics and decentralized care settings

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Point of Care Molecular Diagnostics Market, by Product Type

  • 8.1. Introduction
  • 8.2. Instruments
  • 8.3. Reagents & Kits
  • 8.4. Software

9. Point of Care Molecular Diagnostics Market, by Technology

  • 9.1. Introduction
  • 9.2. Genetic Sequencing-based
  • 9.3. Hybridization-based
  • 9.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 9.5. Microarray-based
  • 9.6. PCR-based

10. Point of Care Molecular Diagnostics Market, by Application

  • 10.1. Introduction
  • 10.2. Cardiology
  • 10.3. Genetic Testing
    • 10.3.1. Carrier Screening
    • 10.3.2. Newborn Screening
    • 10.3.3. Prenatal Testing
  • 10.4. Infectious Disease
    • 10.4.1. Gastrointestinal Infections
    • 10.4.2. Respiratory Infections
    • 10.4.3. Sexually Transmitted Infections
    • 10.4.4. Tropical Diseases
  • 10.5. Oncology
    • 10.5.1. Liquid Biopsy
    • 10.5.2. Mutation Profiling
    • 10.5.3. Oncogene Panel

11. Point of Care Molecular Diagnostics Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Diagnostic Laboratories
  • 11.4. Home Care Settings
  • 11.5. Hospitals

12. Americas Point of Care Molecular Diagnostics Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Point of Care Molecular Diagnostics Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Point of Care Molecular Diagnostics Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. Becton, Dickinson and Company
    • 15.3.3. ACON LABS INC.
    • 15.3.4. Binx Health, inc.
    • 15.3.5. bioMerieux SA
    • 15.3.6. Cardinal Health, Inc.
    • 15.3.7. Chembio Diagnostics Inc.
    • 15.3.8. Co-Diagnostics, Inc.
    • 15.3.9. Danaher Corporation
    • 15.3.10. DiaSorin S.p.A
    • 15.3.11. EKF Diagnostics Holdings
    • 15.3.12. FHoffmann-La Roche AG
    • 15.3.13. Genomadix Inc. by LuminUltra Technologies Ltd.
    • 15.3.14. Henry Schein, Inc.
    • 15.3.15. Meridian Bioscience, Inc.
    • 15.3.16. Novartis AG
    • 15.3.17. OraSure Technologies, Inc.
    • 15.3.18. Pfizer, Inc.
    • 15.3.19. QIAGEN N.V.
    • 15.3.20. Quidel Corporation
    • 15.3.21. SD Biosensor
    • 15.3.22. Sekisui Diagnostics
    • 15.3.23. SHUWEN BIOTECH CO., LTD
    • 15.3.24. Siemens Healthineers AG
    • 15.3.25. Sysmex Corporation
    • 15.3.26. Thermo Fisher Scientific Inc.

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCHAI
  • FIGURE 24. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 25. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCHCONTACTS
  • FIGURE 26. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC SEQUENCING-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC SEQUENCING-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TROPICAL DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TROPICAL DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MUTATION PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MUTATION PROFILING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOGENE PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOGENE PANEL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 77. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 81. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 91. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 93. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 94. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 95. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 96. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 97. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 98. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 99. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 100. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 101. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 102. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 103. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 105. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 106. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 107. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 109. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 110. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 111. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 112. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 113. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 114. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 115. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 116. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 117. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 118. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 119. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 121. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 123. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 124. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 125. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 126. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 127. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 128. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 129. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 130. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 131. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 132. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 133. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 135. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 137. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 139. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 141. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 142. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 143. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 144. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 145. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 146. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 147. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 149. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 151. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 153. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 154. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 155. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 156. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 157. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 158. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 159. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 160. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 161. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 179. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 181. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 193. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 195. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 197. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 199. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 200. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 201. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 202. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 203. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 205. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 207. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 211. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 213. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 214. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 215. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 216. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 217. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 219. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 221. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 223. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 225. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 227. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 228. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 229. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 230. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 231. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 233. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 235. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 239. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 241. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 242. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 243. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 244. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 245. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 247. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 249. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 251. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 253. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 255. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 256. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 257. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 258. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 259. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 261. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 263. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 281. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 283. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 284. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
  • TABLE 285. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 286. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 287. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 289. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)

TABLE 29